secwatch / observer

8-K filed May 29, 2026, 3:27 PM ET CIK 0001911321

other material confidence high sentiment neutral materiality 0.50

Kennedy Lewis Capital reports NAV per share $20.12-$20.16; aggregate NAV $744M

Kennedy Lewis Capital Co

NAV per share: Class I $20.16, Class S $20.12, Class D $20.16 as of April 30, 2026.
Aggregate net asset value $744,043,459; portfolio fair value $1,111,701,368.
Continuous offering up to $2.0B; total 32,947,420 shares issued for $664,064,863 across public and private offerings.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001911321-26-000021
form_type: 8-K
ticker: null
cik: 0001911321
company_name: Kennedy Lewis Capital Co
filed_at: 2026-05-29T19:27:51+00:00
discovered_at: 2026-05-29T19:29:00.890463+00:00
generated_at: 2026-05-29T19:29:16.147492+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001911321-26-000021
json_url: https://secwatch.observer/filing/0001911321-26-000021.json
markdown_url: https://secwatch.observer/filing/0001911321-26-000021.md
text_url: https://secwatch.observer/filing/0001911321-26-000021.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1911321/000191132126000021/0001911321-26-000021-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1911321/000191132126000021/ck0001911321-20260529.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

SYRE

Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030

Spyre Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

ORKA

Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030

Oruka Therapeutics, Inc. June 1, 2026, 4:01 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Via Renewables to redeem all 1,884,935 shares of its 8.75% Series A Preferred at $25.00 per share plus dividends

Via Renewables, Inc. June 1, 2026, 3:06 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

BUKS

CEO Christopher Reedy discloses ongoing cancer treatment; remains in role

BUTLER NATIONAL CORP June 1, 2026, 12:41 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CPSH

CPS Technologies closes $9.6M registered direct offering of 1.2M shares at $8.00/share

CPS TECHNOLOGIES CORP/DE/ June 1, 2026, 9:35 AM ET other_material Items 1.01, 5.03, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

ONCY

Oncolytics reports positive initial preclinical data for pelareorep + RAS inhibitors; further studies planned

ONCOLYTICS BIOTECH INC June 1, 2026, 9:06 AM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CLIR

ClearSign Technologies prices 777,780-share public offering at $4.33/share for ~$3.37M gross proceeds

ClearSign Technologies Corp June 1, 2026, 8:30 AM ET other_material Items 1.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

RDAC

Shareholders approve SPAC extension to Oct 15, 2027; ~1.9M shares redeemed

Rising Dragon Acquisition Corp. June 1, 2026, 6:08 AM ET other_material Items 1.01, 5.03, 5.07, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001911321-26-000021

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.